Diaceutics (LON:DXRX) Trading Up 0.8% - Should You Buy?

Diaceutics PLC (LON:DXRX - Get Free Report) shares shot up 0.8% on Monday . The company traded as high as GBX 128.25 ($1.66) and last traded at GBX 128.25 ($1.66). 58,412 shares traded hands during trading, a decline of 54% from the average session volume of 126,544 shares. The stock had previously closed at GBX 127.20 ($1.64).

Wall Street Analysts Forecast Growth

DXRX has been the subject of several analyst reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a GBX 160 ($2.07) price target on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group restated a "buy" rating and issued a GBX 160 ($2.07) price objective on shares of Diaceutics in a report on Tuesday, December 17th.

Diaceutics Stock Performance

The stock has a 50 day moving average of GBX 138.76 and a 200 day moving average of GBX 130.40. The company has a market capitalization of £105.49 million, a price-to-earnings ratio of -37.07 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39.

Insider Transactions at Diaceutics

In other Diaceutics news, insider Graham Paterson acquired 11,643 shares of the stock in a transaction dated Thursday, January 30th. The stock was purchased at an average cost of GBX 138 ($1.78) per share, with a total value of £16,067.34 ($20,745.44). Corporate insiders own 34.30% of the company's stock.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.